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The aim of this cross-sectional study was to see whether genetic polymorphisms of the enzymes CYP1A1, GSTM1, and 
GSTT1 are associated with higher risk of coronary artery disease (CAD) and whether they affect lipid profile in 252 
subjects living near a natural gas plant, who are likely to be exposed to polycyclic aromatic hydrocarbons (PAHs). Fasting 
serum concentrations of biochemical parameters were determined with standard methods. Genetic polymorphisms of 
CYP 1A1 rs4646903, rs1048943, rs4986883, and rs1799814 were genotyped with polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFPL), while GSTM1 and GSTT1 deletions were detected with multiplex PCR. 
Cardiovascular risk was assessed with Framingham risk score, and the subjects divided in two groups: >10% risk and 
≤10% risk. The two groups did not differ in the genotype frequencies. MANCOVA analysis, which included lipid 
parameters, glucose, and BMI with sex, age, hypertension and smoking status as covariates, showed a significant difference 
between the GSTT1*0 and GSTT1*1 allele carriers (p=0.001). UNIANCOVA with same covariates showed that total 
cholesterol and triglyceride levels were significantly higher in GSTT1*1 allele carriers than in GSTT1*0 carriers (p<0.001 
and p=0.006, respectively). Our findings suggest that CYP1A1, GSTM1, and GSTT1 polymorphisms are not associated 
with the higher risk of CAD, but that GSTT1 affects lipid profile.
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Coronary artery disease (CAD) is one of the most 
frequent causes of death in the world, yet we still do not 
know all the factors that increase CAD risk, and research 
has recently focused on different genetic, lifestyle, and 
environmental factors (1, 2).
Persistent organic compounds like polycyclic aromatic 
hydrocarbons (PAHs) can affect the expression of 
cytochrome P450 (CYP) and glutathione S-transferases 
(GST) genes (3). PAHs are environmental pollutants 
produced by fossil fuel combustion, industrial and natural 
emission, and many other sources (4). Humans are mostly 
exposed to PAHs through the use of materials that contain 
them, through exhaust inhalation, and through tobacco 
smoke (5).
Literature points to the involvement of PAHs in 
carcinogenesis as well as atherosclerosis through 
inflammatory process and DNA-adduct formation (6, 7). 
Furthermore, PAHs can affect the expression of cytochrome 
P450 (CYP) and glutathione S-transferase (GST) genes, 
which produce the respective first and second-phase 
biotransformational enzymes (8, 9).
P4501A1 (CYP1A1) is important for the liver oxidation 
of lyophilic substrates like PAH (10) and have several 
polymorphisms: m1=3801 T>C (11); m2=2455 A>G (12); 
m3=3205 T>C (13) and m4=2453 C>A (14).
Through conjugation with glutathione GST participates 
in organism defence against mutations and oxidative stress 
that lead to atherosclerosis. As its activity depends on the 
GST gene polymorphisms, these may increase the risk of 
carcinogenesis and inflammatory processes (15).
There are three families of glutathione-S transferases: 
microsomal, mitochondrial, and cytosolic (15). The most 
frequent isoforms of the cytosolic family are alpha (GSTA), 
mu (GSTM), pi (GSTP), sigma (GSTS), omega (GSTO), 
zeta (GSTZ), and theta (GSTT). This is the family of 
enzymes that detoxify reactive electrophilic compounds but 
is also involved in lipid metabolism and biosynthesis of 
lipid-derived biogenic compounds (15). Human GSTM1 
and GSTT1 genes exhibit a very common polymorphism 
that partially or completely deletes those genes and their 
enzymes (16).
Even though average PAH air pollution at the Molve 
(Croatia) natural gas processing plant does not seem to 
exceed regulatory limits, seasonal variations may trigger 
processes associated with gene expression and the risk of 
CAD. This may especially be true for GST polymorphisms 
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that increase organism sensitivity to genotoxic compounds. 
The (primary) aim of this study was to see whether genetic 
polymorphisms of the enzymes CYP1A1, GSTM1, and 
GSTT1 are associated with the higher risk of CAD and 
whether they affect lipid profile in people who may be 
exposed to polycyclic aromatic hydrocarbons (PAHs).
PARTICIPANTS AND METHODS
Study participants and design
The data and samples for this cross-sectional study were 
collected between 2007 and 2009. It included 252 adult 
participants from the general population who had been 
living near a natural gas plant in the rural community of 
Molve for over 10 years. The participants were recruited 
in collaboration with the local primary healthcare clinic and 
all who agreed to participate signed an informed consent 
form. The study was approved by the Ethics Committee of 
the Zagreb University School of Medicine.
Fasting blood samples were collected in collaboration 
with family medicine physicians. Whole blood was 
collected into the K2EDTA tubes and serum separator 
Vacutainer tubes (Terumo Europe, Leuven, Belgium) for 
DNA extraction and serum separation. Sera were stored at 
-20 °C until analyses.
Family history of cardiovascular diseases and individual 
risk factors for atherosclerosis (hypertension, smoking, and 
alcohol consumption) was taken with a questionnaire. 
Smokers were defined as either ex-smokers or active 
smokers, while non-smokers were those who had never 
smoked. Height and weight were taken to calculate the body 
mass index (BMI). Blood pressure was measured in the 
sitting position, after 10-20 min of rest. Diabetes mellitus 
was determined according to the WHO diagnostic criteria 
(17) and history of insulin or oral glucose-lowering therapy.
Cardiovascular risk was assessed by calculating the 
Framingham risk score from the following information: 
age, sex, T-cholesterol, HDL-cholesterol, smoking status, 
systolic blood pressure, and blood pressure treatment (18). 
We used a web calculator available at https://www.
easycalculation.com/medical/framingham.php. This tool is 
used to assess the risk of coronary heart diseases and/or 
severe outcomes like myocardial infarction or coronary 
death in the next 10 years. We determined three categories 
of cardiovascular risk for sever cardiovascular outcome in 
the next 10 years(19): above 20 %, between 10-20 % and 
below 10 %. As only a few participants ran the risk above 
20 %, we merged them with the group with high risk of 
CAD (>10%). The second group ran low risk (≤10%). As 
the Framingham score algorithm tolerates the risk of up to 
30 %, five participants were excluded from the analysis.
Blood serum analysis
Concentrations of total cholesterol, HDL-cholesterol, 
triacylglycerol, and glucose were determined on a COBAS 
INTEGRA 400+ analyser (Roche Diagnostics, Mannheim, 
Germany) following the standard procedure. LDL-
cholesterol was calculated with the Friedwald equation.
DNA analysis
DNA was extracted with the salting-out method (20) 
and four CYP1A1 genetic polymorphisms determined with 
polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP): m1=3801 T/C (rs4646903), 
m2=2455 A/G Ile/Val (rs1048943); m3=3205 T/C 
(rs4986883) and m4=2453 C/A Thr/Asp (rs1799814). PCR 
was performed using oligonucleotides from TibMolBiol 
(Berlin, Germany) created according the sequence from 
literature (21, 22).
PCR reactions were performed on an Eppendorf 
Mastercycler® 3350 (Eppendorf, Hamburg, Germany). The 
PCR-reaction mixture of 25 µL consisted of 500 ng of 
genomic DNA, 0.6 µmol L-1 of each primer, 10-3 µmol L-1 
of MgCl2, 0.25 µmol L
-1 of each dNTP, and 0.75 U of 
FastStart TaqDNA Polymerase (Roche, Manheim, 
Germany). The reactions started with denaturation at 94 °C 
for 2 min. Each of the 35 cycles that followed consisted of 
30 s at 94 °C, 30 s at 63 °C, and 1 min at 72 °C, followed 
by a 7-min extension at 72 °C. The 899-bp-long fragment 
(m1 & m3) was digested with Msp I (Roche Diagnostics, 
Manhem, Germany) to yield 693- and 206-bp-long 
fragments in the presence of the m1 polymorphism and 
802- and 97-bp-long fragments in the presence of the m3 
polymorphism. The 204-bp-long fragment (m2 & m4) was 
digested with BsrDI and BsaI (Fermentas International Inc., 
Burlington, Canada) to yield 149- and 55-bp-long fragments 
in the presence of the m2 polymorphism and 139- and 
65-bp-long fragments in the presence of the m4 
polymorphism. The fragments were detected on 2 % agarose 
gel stained with ethidium-bromide.
GSTM1 and GSTT1 deletions (GSTM1*0 and GSTT1*0 
alleles) were detected with the multiplex-PCR method with 
three pairs of nucleotides (TibMolBiol, Berlin, Germany) 
created according to the sequence from literature (16). In 
short, two pairs of oligonucleotides served to anneal the 
GSTM1 and GSTT1 fragments without deletion, while the 
third pair served to anneal the GSTM4 fragment as control 
without deletion. The fragments were detected on 2 % 
agarose gel stained with ethidium-bromide. The 230- and 
480-bp-long fragments corresponded to the respective 
GSTM1 and GSTT1 positive genotypes with at least one 
functional allele (GSTM1*1 and GSTT1*1). The 157-bp-
long fragments corresponded to GSTM4 as an internal 
control. PCR reactions started with denaturation at 94 °C 
for 5 min, followed by 35 cycles, each consisting of 1 min 
at 94 °C, 1 min at 52 °C and 1 min at 72 °C, followed by a 
7-min extension at 72 °C.
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The PCR for every 10th sample was repeated and DNA 
concentrations adjusted. For all samples with unsuccessful 
PCR or RFLP we repeated the procedure.
Statistical analysis
For statistical analysis we used Statistica 12 (Tulsa, OK, 
USA). Categorical variables were tested with Pearson’s 
chi-square test. Continuous variables were expressed as 
means with standard deviations or medians and 25th to 75th 
quartile, depending on distribution normality. For multiple 
testing with sex, age, diabetes mellitus, hypertension, and 
smoking status as covariates we used multivariate analysis 
of variance (MANCOVA). For this purpose triglycerides 
were log-transformed.
The level of significance was set at 0.05. To account for 
multiple ANOVAs we used Bonferroni correction due to 
multiple comparisons. The Bonferroni correction sets the 
significance cut-off at α/11 for MANCOVA and α/5 for 
UNIANCOVA.
RESULTS
Table 1 shows the biochemical and anthropometric 
information about the study participants by risk groups. As 
expected, they significantly differed in all risk factors. 
Besides, the high-risk group had significantly more 
diabetics, higher BMI, glucose, and triglyceride 
concentrations than the low-risk group.
However, the two groups did not differ in genotype 
frequencies of CYP1A1m1, CYP1A1m2, CYP1A1m4, 
GSTM1, and GSTT1 (Table 1). According to Hardy-
Weinberg proportions, genotypes are expected to be in 
equilibrium. The chi-square test p values for calculating the 
differences between the observed and expected genotype 
frequencies in the low-risk group were 0.459, 0.211, and 
0.406 for CYP1A1-m1, m2, and m4, respectively. In the 
high-risk group, the p values for the same genotypes were 
0.098, 0.952, and 0.789, respectively. As the frequency of 
rare homozygous genotypes for all three polymorphisms 
was low, we merged them with the frequencies of 
heterozygotes into one category as “rare allele carriers”. 
CYP1A1-m3 was not detected in any of the participants. 
There was no difference in frequencies of wild and rare 
allele carriers.
Table 2 shows the associations between biochemical 
and anthropometric parameters and the polymorphisms, 
except for the 18 participants with diabetes, because 
diabetes affects lipid profile. A significant difference in lipid 
levels was found with MANCOVA between the GSTT1-0 
and GSTT1-1 allele carriers (p=0.001; F=3.65), while the 
CYP1A1m1, CYP1A1m2, CYP1A1m4, and GSTM1 
genotypes were not associated with lipid levels. Univariate 
Table 1 General biochemical and anthropometric characteristics and genotype frequencies in low- and high-risk groups (according 
to the Framingham risk score)
Parameter* Low-risk group  (CAD risk Ł
High-risk group  
(CVD risk >10%)  
N=71
P
Age 43  (min-max:18-78)
63  
(min-max:34-80) <0.001
Sex: male, N (%) 39 (22.2) 47 (66.2) <0.001
Hypertension: yes, N (%) 62 (35.2) 55 (77.5) <0.001
Diabetes: yes, N (%) 5 (2.8) 13 (18.3) <0.001
Smoking: yes, N (%) 60 (34) 37 (52) 0.001
CYP1A1/m1 3801TT*, N 142 60 0.275CYP1A1/m1 3801TC+CC**, N 27 (25+2) 7 (6+1)
CYP1A1/m2 2455AA*, N 161 70 0.074CYP1A1/m2 2455AG+GG**, N 14 (13+1) 1 (1+0)
CYP1A1/m4 2453CC*, N 138 51 0.237CYP1A1/m4 2453CA+AA**+; N 37 (36+1) 20 (18+2)
GSTM1*1, N 105 42 0.863GSTM1*0, N 69 29
GSTT1*1, N 123 51 0.395GSTT1*0, N 54 17
BMI, kg m-2 27.32±5.23 30.15±5.27 <0.001
Total-cholesterol, mmol L-1 5.41±1.03 5.88±1.17 0.002
HDL-cholesterol, mmol L-1 1.30±0.37 1.04±0.32 <0.001
LDL-cholesterol, mmol L-1 3.40±0.92 4.05±3.17 0.014
Triglycerides, mmol L-1, median (25th; 75th quartile) 1.36  (0,96; 1.97)
1.93  
(1.46; 3,52) <0.001
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analysis with the same covariates singled out total 
cholesterol and triglyceride concentrations as significantly 
higher in the positive GSTT1 allele carriers than in the 
GSTT1-0 carriers (p<0.001 and P=0.006, respectively). 
Triglyceride concentrations were also different between the 
CYP1A1-m1 carriers and non-carriers, but the difference 
was marginally significant due to the Bonferroni correction.
Table 3 shows biochemical parameters and BMI in 
CYP1A-m1 and GSTT-1 polymorphism carriers who showed 
significant differences with the MANCOVA and 
UNIANCOVA analyses. 
The GSTT1*1 positive allele was significantly more 
common in subjects with serum triglyceride and total 
cholesterol concentrations above the 75th quartile than in 
subjects with these values below the 25th quartile. No such 
difference was observed for the CYP1A1-m1 carrier 
frequencies (Table 4).
DISCUSSION
Our findings suggest that CYP1A1, GSTT1, or GSTM1 
genetic polymorphisms have not affected CAD risk in 
people who live near the natural gas processing plant. 
However, we have found a significant influence of the 
GSTT1 deletion polymorphism on lipid parameters, serum 
triglyceride and total cholesterol in particular, after 
adjustment for sex, age, hypertension, and smoking status.
Our Molve population (Croatian northwest) has similar 
distribution of the CYP 1A1-m1, GSTM1, and GSTT1 
polymorphisms to the frequencies reported in other Croatian 
studies: the GSTM1 and GSTT1 deletion polymorphisms 
in pulmonary patients from Zagreb (23) and the CYP1A1-m1 
(3801 T/C) polymorphism in urologic male patients form 
Osijek (24).
To the best of our knowledge these polymorphisms have 
not been investigated in relation to CAD in any Croatian 
population study. There are, however, several studies that 
investigated the association of the CYP1A1-m1, m-2, m4, 
GSTM1, and GSTT1 polymorphisms with CAD in other 
countries. In Slovenian patients with diabetes mellitus the 
GSTT1-0 deleted genotype was associated with an increased 
risk of carotid atherosclerosis. GSTM1 and GSTT1 
polymorphisms, however, were not significantly associated 
with lipid parameters (25). In Italy, Manfredi et al. (26) 
found no significant differences in CYP1A1 genotypes 
frequencies between smokers with CAD and without CAD, 
but did establish a significant association between combined 
GSTM1 (null) plus GSTT1(null) genotypes and CAD risk. 
In Turkey, a significant CAD risk was established in the 
carriers of the CYP1A1 variant plus GSTT1 null genotype 
(27).
There are but a few studies that examine the association 
between lipids and CYP1A1 polymorphisms, but none in 
European populations. In a Mexican study, CYP1A1-m2 
allele was significantly associated with high triglycerides 
Table 2 Effects of genetic polym
orphism
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(28), and in a Brazilian study in postmenopausal women 
the same allele was associated with high HDL-cholesterol 
(29). Unlike these studies, we have found no association 
between any of the CYP1A1 polymorphisms and lipid 
parameters and neither has a Japanese study in women with 
osteopenia or osteoporosis (30).
Furthermore, unlike other studies in non-European 
populations, GSTT1 positive allele in our study was 
associated with hypertriglyceridemia (31-33).
As our results related to association of lipids and GSTT1 
polymorphism were opposite to literature data, we try to 
explain that with insights that are also presented in the 
literature. Inter alia, triacylglycerol metabolism includes 
activities of lipoprotein lipase, PPARγ – receptor and 
prostaglandin derivatives. As, active enzyme glutathione 
transferase catalyses the conjugation of prostaglandin 
derivative 15d-PG-J2 with glutathione, it therefore prevents 
PPARγ activation (34). Namely, 15d-PG-J2 may act as main 
endogenous ligand for the gamma isoform of the PPAR-
receptors and if it is conjugate it cannot bind PPARγ receptor 
(34). Due the absence of PPARγ activation, one of the main 
it’s roles, cannot be expressed. Active PPARγ pronounces 
triglyceride-lowering effects because it’s activation induces 
adipose tissue LPL gene expression, resulting in a more 
efficient lipolysis and clearance of triglycerides from 
circulation (35, 36). Therefore we supposed that different 
conditions which leads to different genetic expression might 
be involved in lowering of lipid concentrations in GSTT1-
0, null allele carriers.
The added value of this study is that it brings original 
population polymorphism data for the Molve area so that 
we can see how it stands in relation to other Croatian 
population studies and some other European populations, 
but could not compare lipid associations with the studied 
polymorphisms, as the data only exist for non-European 
populations.
The study is limited by its small sample, narrow 
geographical area, and lack of data about PAH exposure 
(such as urinary PAH metabolites) because this population 
lives near a natural gas processing plant.
In conclusion, genetic polymorphisms of the enzymes 
CYP1A1, GSTM1, and GSTT1 are not associated with the 
higher risk of coronary artery disease (CAD), and only 
GSTT1 seems to affect the lipid profile of the Molve 
population.
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Genski polimorfizmi enzima CYP1A, GSTM1 i GSTT1 i njihov utjecaj na rizik od kardiovaskularne bolesti i 
lipidni profil u ispitanika koji su nastanjeni u blizini crpilišta prirodnog plina
Cilj ovog presječnog istraživanja bio je ispitati moguću povezanost između genskih polimorfizama enzima i većeg rizika 
od koronarne arterijske bolesti (KAB) i promjena koncentracija lipida u krvi. U istraživanje su bila uključena 252 ispitanika 
koja više od deset godina prebivaju u blizini crpilišta prirodnog plina, zbog čega bi mogli biti izloženi utjecaju policikličkih 
aromatskih ugljikovodika. Koncentracije biokemijskih analita određene su standardnim metodama u serumu izdvojenome 
iz krvi uzete natašte. Genski polimorfizmi CYP 1A1 rs4646903, rs1048943, rs4986883 i rs1799814 utvrđeni su pomoću 
lančane reakcije polimerazom i metode ispitivanja polimorfizama duljine restrikcijskih ulomaka (PCR-RFLP). Delecije 
gena GSTM1 i GSTT1 utvrđene su pomoću višestruke lančane reakcije polimerazom. Rizik od kardiovaskularnih bolesti 
izračunan je pomoću Framinghamove procjene rizika, na temelju kojega su ispitanici podijeljeni u dvije skupne: rizik > 
10 % i rizik ≤ 10 %. Ove dvije skupine nisu se razlikovale prema učestalosti ispitivanih genotipova. Analiza MANCOVA, 
koja je uključivala lipidne analite, glukozu i indeks tjelesne mase te četiri kovarijata (spol, dob, hipertenziju i pušenje), 
pokazala je statistički značajnu razliku između nositelja GSTT1*0 i GSTT1*1 alela (p = 0,001). UNIANCOVA analiza 
s istim kovarijatama pokazala je da su vrijednosti kolesterola i triacilglicerola značajno više u nositelja GSTT1*1 alela 
nego u nositelja GSTT1*0 (p < 0,001 i p = 0,006). Na temelju naših rezultata može se pretpostaviti da polimorfizmi u 
genima za CYP1A1, GSTM1 i GSTT1 nisu povezani s većim rizikom od kardiovaskularnih bolesti, ali da polimorfizam 
u genu za GSTT1 može utjecati na lipidni profil.
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